Literature DB >> 24508139

Unexpected coronary artery findings in mucopolysaccharidosis. Report of four cases and literature review.

Elizabeth Braunlin1, Paul J Orchard2, Chester B Whitley3, Luke Schroeder2, Robyn C Reed4, J Carlos Manivel5.   

Abstract

INTRODUCTION: The mucopolysaccharidosis syndromes are a group of lethal inherited disorders affecting multiple organ systems by the progressive deposition of glycosaminoglycan. Advances in treatment such as enzyme replacement and hematopoietic stem cell transplantation have significantly improved the outcome of these disorders. An in-depth understanding of the pathophysiology of heart disease in these disorders is essential since death from cardiac causes continues to be common. Epicardial coronary artery luminal narrowing from myointimal proliferation and glycosaminoglycan deposition is well described in severe mucopolysaccharidosis type I [Hurler syndrome, mucopolysaccharide IH] but poorly understood in other "non-Hurler" phenotypes of these disorders. Given the rarity of these conditions, autopsy specimens are uncommon.
METHODS: Tissue from epicardial coronary arteries from autopsies of four patients with non-Hurler mucopolysaccharidosis (attenuated type I, type IIIA, type IIIC, and type VI) who had died after hematopoietic cell transplantation (within 1 month in three cases; after 5 years in the fourth) was examined by light microscopy.
RESULTS: Unexpectedly, near-normal coronary arteries were observed in the patient with attenuated mucopolysaccharidosis type I, while the coronaries from patients with type IIIA, IIIC, and VI demonstrated classic histologic features of glycosaminoglycan deposition. The most severe findings were found in the MPS IIIC patient who had 5 years of full donor engraftment after transplantation.
CONCLUSIONS: Our current understanding of the cardiac manifestations of the mucopolysaccharidoses fails to explain why near-normal coronary arteries may be observed when abnormalities would be most likely to be expected and, conversely, why significant histopathology is present when it would be least expected. Identification of downstream effects of glycosaminoglycan deposition may identify other metabolites or metabolic pathways that are important in the clinicopathologic manifestations of these diseases.
SUMMARY: The mucopolysaccharidosis diseases are a group of inherited disorders affecting multiple organ systems by the progressive deposition of glycosaminoglycan. Severe coronary artery disease is well recognized in severe type I mucopolysaccharidosis (Hurler syndrome), but unexpected coronary artery disease occurs in other, "non-Hurler" mucopolysaccharidoses. Factors responsible for the development of coronary pathology in the mucopolysaccharidoses remain elusive.
Copyright © 2014 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Coronary artery; Glycosaminoglycan; Mucopolysaccharidosis

Mesh:

Substances:

Year:  2014        PMID: 24508139     DOI: 10.1016/j.carpath.2014.01.001

Source DB:  PubMed          Journal:  Cardiovasc Pathol        ISSN: 1054-8807            Impact factor:   2.185


  11 in total

Review 1.  Skeletal dysplasias: A radiographic approach and review of common non-lethal skeletal dysplasias.

Authors:  Ananya Panda; Shivanand Gamanagatti; Manisha Jana; Arun Kumar Gupta
Journal:  World J Radiol       Date:  2014-10-28

2.  Immune-Mediated Inflammation May Contribute to the Pathogenesis of Cardiovascular Disease in Mucopolysaccharidosis Type I.

Authors:  Omar Khalid; Moin U Vera; Philip L Gordts; N Matthew Ellinwood; Philip H Schwartz; Patricia I Dickson; Jeffrey D Esko; Raymond Y Wang
Journal:  PLoS One       Date:  2016-03-17       Impact factor: 3.240

3.  Aortic Root Dilatation in Mucopolysaccharidosis I-VII.

Authors:  Meena Bolourchi; Pierangelo Renella; Raymond Y Wang
Journal:  Int J Mol Sci       Date:  2016-11-29       Impact factor: 5.923

4.  Residual glycosaminoglycan accumulation in mitral and aortic valves of a patient with attenuated MPS I (Scheie syndrome) after 6 years of enzyme replacement therapy: Implications for early diagnosis and therapy.

Authors:  Yohei Sato; Masako Fujiwara; Hiroshi Kobayashi; Michio Yoshitake; Kazuhiro Hashimoto; Yuji Oto; Hiroyuki Ida
Journal:  Mol Genet Metab Rep       Date:  2015-11-08

5.  The Carotid Intima-Media Thickness and Arterial Stiffness of Pediatric Mucopolysaccharidosis Patients Are Increased Compared to Both Pediatric and Adult Controls.

Authors:  Raymond Y Wang; Kyle D Rudser; Donald R Dengel; Elizabeth A Braunlin; Julia Steinberger; David R Jacobs; Alan R Sinaiko; Aaron S Kelly
Journal:  Int J Mol Sci       Date:  2017-03-15       Impact factor: 5.923

6.  Risks of long-term port use in enzyme replacement therapy for lysosomal storage disorders.

Authors:  Christian J Hendriksz; Paul Harmatz; Roberto Giugliani; Jane Roberts; G Suren Arul
Journal:  Mol Genet Metab Rep       Date:  2018-03-07

Review 7.  Early diagnosis and management of cardiac manifestations in mucopolysaccharidoses: a practical guide for paediatric and adult cardiologists.

Authors:  Lucia Boffi; Pierluigi Russo; Giuseppe Limongelli
Journal:  Ital J Pediatr       Date:  2018-11-16       Impact factor: 2.638

8.  Mitral Regurgitation and Heart Failure as the First Presentation in a Patient with Features of Two Connective Tissue Disorders: A Rare Combination of Mucopolysaccharidosis and Osteogenesis Imperfecta?

Authors:  Yasuhiro Hamatani; Junko Nakashima; Keiko Ohta-Ogo; Makoto Amaki; Masashi Koga; Daisetsu Aoyama; Kyohei Marume; Kenichiro Sawada; Yasuteru Nakashima; Atsushi Shibata; Atsushi Okada; Hiroyuki Takahama; Takuya Hasegawa; Yasuo Sugano; Hideaki Kanzaki; Yoshihiko Ikeda; Satoshi Yasuda; Hatsue Ishibashi-Ueda; Toshihisa Anzai
Journal:  Intern Med       Date:  2017-12-08       Impact factor: 1.271

9.  The use of port-a-caths in adult patients with Lysosomal Storage Disorders receiving Enzyme Replacement Therapy-one centre experience.

Authors:  Mairead McLoughlin; Karolina M Stepien; Briony McNelly; Lorraine Thompson; Janet Gorton; Christian J Hendriksz
Journal:  Mol Genet Metab Rep       Date:  2017-10-21

Review 10.  Lysosome Function in Cardiovascular Diseases.

Authors:  Owais M Bhat; Pin-Lan Li
Journal:  Cell Physiol Biochem       Date:  2021-05-22
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.